Saturday, October 10, 2026

New York Times Stock Is 14% Up At Session Start On Wednesday

ViaNews Editorial Team

February 8, 2023

New York Times Stock Is 14% Up At Session Start On Wednesday

(VIANEWS) - Shares of New York Times (NYSE: NYT) rose by a staggering 14.6% to $42.07 at 10:09 EST on Wednesday, after two consecutive sessions in a row of gains. NYSE is rising 0.79% to $16,021.62, following the last session's upward trend. This seems, at the moment, a somewhat positive trend trading session today.

New York Times's last close was $36.71, 22.99% under its 52-week high of $47.67.

About New York Times

The New York Times Company, together with its subsidiaries, provides news and information for readers and viewers across various platforms worldwide. It offers The New York Times (The Times), a daily and Sunday newspaper in the United States, as well as international edition of The Times; and operates the NYTimes.com Website. The company also transmits articles, graphics, and photographs from The Times and other publications to approximately 1,500 newspapers, magazines, and websites; licenses electronic databases to resellers in the business, professional, and library markets; and offers magazine licensing, news digests, book development, and rights and permissions. In addition, it engages in the live events business, which hosts physical and virtual live events to connect audiences with journalists and outside thought leaders; direct-sold website, mobile application, podcast, email, and video advertisements, as well as digital advertising services; operates Wirecutter, a product review and recommendation products; develops mobile applications, including games and cooking products; prints and distributes products for third parties; and offers other products and services. The company was founded in 1851 and is headquartered in New York, New York.

Earnings Per Share

As for profitability, New York Times has a trailing twelve months EPS of $0.6.

PE Ratio

New York Times has a trailing twelve months price to earnings ratio of 70.12. Meaning, the purchaser of the share is investing $70.12 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.91%.

Volatility

New York Times's last week, last month's, and last quarter's current intraday variation average was 1.46%, 0.53%, and 1.22%.

New York Times's highest amplitude of average volatility was 1.83% (last week), 1.13% (last month), and 1.22% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.6%, now sitting on 2.17B for the twelve trailing months.

Sales Growth

New York Times's sales growth is 9.9% for the ongoing quarter and 7.7% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

New York Times's stock is considered to be overbought (>=80).

More news about New York Times (NYT).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,365 source documents archived
Query this data → isubstrate.com